<code id='3CD7667718'></code><style id='3CD7667718'></style>
      • <acronym id='3CD7667718'></acronym>
      <center id='3CD7667718'><center id='3CD7667718'><tfoot id='3CD7667718'></tfoot></center><abbr id='3CD7667718'><dir id='3CD7667718'><tfoot id='3CD7667718'></tfoot><noframes id='3CD7667718'>
      • <optgroup id='3CD7667718'><strike id='3CD7667718'><sup id='3CD7667718'></sup></strike><code id='3CD7667718'></code></optgroup>
        5. <b id='3CD7667718'><label id='3CD7667718'><select id='3CD7667718'><dt id='3CD7667718'><span id='3CD7667718'></span></dt></select></label></b><u id='3CD7667718'></u>
          <i id='3CD7667718'><strike id='3CD7667718'><tt id='3CD7667718'><pre id='3CD7667718'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-27 23:47:40 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：31824
                                  
                                    
          
                                   
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb
          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.
          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.
          advertisement
          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The PBM ad wars are taking over Washington, D.C.
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles